

# PRESS RELEASE

## J.B. CHEMICALS ANNOUNCES Q2 RESULTS

### HIGHLIGHTS

- \* Net Sales up 17% at Rs. 148.15 cr
- \* PBIDT up 13% at Rs. 38.12 cr.
- \* PAT up 12% at Rs. 27.58 cr.
- \* EPS for Q2 up 8% at Rs.3.28 (FV Rs.2/-)
- \* Interim Dividend – 55%

BSE Scrip Code : 506943
-------------------------

NSE Symbol : JBCHEPHARM
-------------------------

**Mumbai, 30<sup>th</sup> October 2006** : J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL), today announced its unaudited financial results for the Second Quarter ended September 30, 2006. The Company achieved a Net Sales of Rs.14814.65 lakhs for the second quarter ended September 30, 2006, as compared with Rs. 12706.57 lakhs for the same period last year, registering a growth of 17%, driven by higher domestic as well as Export businesses. Profit After Tax stood at Rs.2757.75 lakhs (Rs.2453.97 lakhs) reflecting an increase of 12%.

Profit Before Interest, Depreciation and Tax (PBIDT) is Rs.3811.52 lakhs (Rs.3372.25 lakhs), registering an increase of 13%, Interest is at Rs.251.97 lakhs (Rs.97.79 lakhs). Depreciation claims Rs.355.00 lakhs (Rs. 300.00 lakhs) and Provision for Taxation is Rs.320.58 lakhs (Rs.451.80 lakhs). Deferred Tax is Rs.101.22 lakhs (Rs.35.00 lakhs). The Profit after Taxation for the year is Rs.2757.75 lakhs (Rs.2453.97 lakhs), registering an increase of 13%. The Basic & Diluted Earnings Per Share (FV Rs.2/-) for the second quarter ended September 30, 2006 is Rs.3.28 (Rs.3.05). The company has been investing in expanding and strengthening its Manpower resources both in the domestic & Export businesses, the benefit of which will flow in the near future.

Thus, H1 (1<sup>st</sup> April – 30<sup>th</sup> September 2006) Net Sales stood at Rs.24940.01 lakhs, up 13% from Rs.22169.00 lakhs in the previous year and PAT is Rs.4058.87 lakhs as against Rs.3635.61 lakhs, up 12%. The basic and diluted Earnings Per Share (FV Rs.2/-) is Rs.4.83 (Rs.4.52).

The Board has declared an Interim Dividend of Rs.1.10 (55%) per equity share, on an enhanced capital base of Rs.1685.99 lakhs divided into 8,42,99,425 equity shares of Rs.2/- each, fully paid-up, for which November 14, 2006 has been fixed as the Record Date.

International business continues to be one of the key growth driver for the Company. Nearly 44% of the Company's turnover of Rs.481.65 crores comes from exports to Russia and CIS. To achieve a twin objective of servicing small as well as regional distributors and ensuring availability of the Company's products on a continuous basis in the Russian market, the Company had set-up a Wholly owned Subsidiary "OOO Unique Pharmaceuticals Laboratories" in Russia, Moscow. The WOS commenced it's commercial operations in Q2FY07. This strategic move Shall help the Company to increase its market share in Russia and CIS countries and maintain its leadership position with introduction of new products and novel technologies in much wider therapeutic fields in the near future.

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine and the other CIS countries. The Company continues to invest in growing its shares in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDA's. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at [www.uniquepharma.com](http://www.uniquepharma.com) / [www.jbcpl.com](http://www.jbcpl.com)

**For more details, please contact:**

Beejal Desai  
Vice President & Company Secretary  
Head Investor Relations  
J. B. Chemicals & Pharmaceuticals Ltd.  
91 22 2499 1311

Kais Rahimtulla  
Madison Public Relations  
91 22 5654 8341/42/43  
9820131613

*Forward Looking Statement :*

This Press Release may contain Forward Looking Statements regarding future events and future performance of J. B. Chemicals & Pharmaceuticals Ltd. that involves risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.